ClinicalTrials.gg
RecruitingNCT07021664MOSAICUpdated Oct 26, 2026

Health, Imaging, and Cognition Across the Menopausal Transition

An observational study in Menopause, sponsored by Université de Sherbrooke. Recruiting at 2 sites in Canada. Open to female participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Université de Sherbrooke · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
45
Ages
35 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Ketosis by Université de Sherbrooke — 4 open to participants now, 5 under way, none of them phase 3. Ketosis · Université de Sherbrooke.

Started
2025
with 1 other
Observational
3 of 18
2 open now
Registered
17th of 18
by date

Among the 18 studies in Ketosis by Université de Sherbrooke, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 17th registered.

Ketosis

218 studies on the registry are indexed under Ketosis; 49 are open to participants now.

Browse Ketosis studies →

Open to participants now

4 of the 18 studies in Ketosis by Université de Sherbrooke are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 31 Ketosis studies recruiting now, 7 (23%) set no upper age limit and 21 (68%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 35 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Ketosis by Université de Sherbrooke, or all of them as a file.
02

Study summary

This observational cross-sectional study aims to better understand how the menopausal transition affects brain energy metabolism and cognition. Menopause, a natural stage in a woman's life, is typically divided into three phases: premenopause, perimenopause, and postmenopause. This transition involves hormonal fluctuations and a decline in estrogen levels, which can impact physical, emotional, and cognitive well-being. Common symptoms include hot flashes, sleep disturbances, mood changes, and difficulties with memory and concentration.

Emerging evidence suggests that the decline in estrogen may impair how the brain uses glucose, its primary energy source. This reduction in glucose metabolism is thought to contribute to cognitive difficulties reported during midlife. In contrast, the brain's capacity to use ketones-alternative energy substrates produced during fasting or low-carbohydrate intake-appears preserved during aging and hormonal changes. Increasing circulating ketones may offer a promising strategy to support brain energy and cognitive function.

To explore these relationships, the study will employ advanced brain imaging (PET scans) to assess glucose and ketone uptake in the brain. Additional measures will include hormone levels, cognitive testing, continuous glucose monitoring, and MRI. PET tracers will also be used to evaluate estrogen receptor distribution, providing insight into how the brain responds to hormonal changes.

A total of 45 women aged 35-60 will be enrolled and categorized into three groups (15 per group): premenopause, perimenopause, and postmenopause. Each participant will attend four study visits that include questionnaires, blood tests, cognitive assessments, metabolic measurements, and imaging procedures.

The results may help identify early neurobiological and metabolic markers associated with the menopausal transition. These findings could inform new approaches to preserve brain health and prevent cognitive decline in aging women. Improving understanding of how the female brain adapts to hormonal shifts may ultimately support more targeted strategies for promoting healthy aging.

03

Conditions studied

  • Menopause

Browse trials for

Keywords

  • menopause
  • cognition
  • metabolism
  • estrogen
  • ketone
  • PET scan
  • estrogen receptor
04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Healthy individuals from the general population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to read and speak French
  • Capable of understanding and signing GROUP SPECIFIC INCLUSION CRITERIA Premenopause: • Women aged 35 to 55; No change in menstrual cycle regularity over the past 10 months (variation less than 7 days per cycle)

Perimenopause: Women aged 40 to 60; Menstrual cycles varying by more than 7 days per cycle for at least 10 cycles, or no period for 3 to 11 months

: Women aged 45 to 65; No menstrual period for ≥ 12 months

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, childbirth within the past 12 months, or breastfeeding
  • Use of hormone replacement therapy or hormonal in the past 6 months
  • to MRI (e.g., presence of non-compatible metallic objects)
  • Claustrophobia
  • Type 1 diabetes
  • Adherence to a ketogenic intervention (e.g., ketone supplements, intermittent fasting, ketogenic diet) in the past 3 months
  • Engaging in intense physical activity 5 times per week or more
  • Any significant neurological disorder (e.g., dementia, brain tumor, seizure disorder, history of significant head trauma with persistent neurological deficits, known structural brain abnormalities)
  • History of oophorectomy or hysterectomy
  • Any significant psychiatric disorder (e.g., major depression within the past 2 years, bipolar disorder, schizophrenia)
  • Systemic diseases or unstable/uncontrolled medical conditions (e.g., cardiovascular disease, uncontrolled diabetes, kidney or liver disorders)
  • Any other condition that may interfere with participation, as judged by the study physician
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
45 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • premenopause

    Women between 35 and 55 years old who still have regular menstrual cycles, with no noticeable changes in the past 10 months.

  • perimenopause

    Women between 40 and 60 years old who have experienced changes in their menstrual cycles, such as irregular timing (varying by more than 7 days) for at least 10 cycles, or no period for 3 to 11 months.

  • postmenopause

    Women between 45 and 65 years old who have not had a menstrual period for 12 months or more.

06

What researchers measure

Primary outcomes

  1. cerebral metabolic rates (μmol/100 g/min) measured by PET (11C-AcAc +18F-FDG)

    Brain energy metabolism will be quantified using two PET tracers: 11C-acetoacetate (for ketone use) and 18F-fluorodeoxyglucose (for glucose use). This will allow comparison of brain fuel usage between three menopausal groups (PRE, PERI, POST).Total Cerebral metabolic rates (μmol/100 g/min) (CMR tot= CMR acac + CMRglu)

    Time frame: 1 day at baseline

  2. Tracer influx rates (k) measured by PET (11C-AcAc +18F-FDG)

    Brain energy metabolism will be quantified using two PET tracers: 11C-acetoacetate (for ketone use) and 18F-fluorodeoxyglucose (for glucose use). This will allow comparison of brain fuel usage between three menopausal groups (PRE, PERI, POST). tracer influx rates (K values).

    Time frame: 1 day at baseline

Secondary outcomes

  1. Time-activity curves of the estrogen receptor in the brain (by 18F-4FMFES PET)

    Time-activity curves of the estrogen recept will be measured using 18F-4FMFES PET express as SUV (Standardized Uptake Value)

    Time frame: 1 day at baseline

  2. distribution volume ratio of the estrogen receptor in the brain (by 18F-4FMFES PET)

    distribution volume ratio of the estrogen receptor will be measured by kinetic modelisation using 18F-4FMFES PET.

    Time frame: 1 day at baseline

  3. Glucose variability (SD of glucose measured by continuous glucose monitoring)

    Continuous glucose monitoring (CGM) will track glucose levels over several days. Glycemic variability will be assessed by the standard deviation of glucose values over the 5 days monitoring period. (mmol/L)

    Time frame: Over 5 days following sensor placement et stabilisation

  4. Glucose average (mean of glucose measured by continuous glucose monitoring)

    Continuous glucose monitoring (CGM) will track glucose levels over several days. Average glucose concentration over the monitoring period.(mmol/L)

    Time frame: Over 5 days following sensor placement et stabilisation

  5. Time in range

    Total minutes with glucose values within the standard glycemic range (3.9-10.0 mmol/L) over the 5 days monitoring period. (min)

    Time frame: Over 5 days following sensor placement et stabilisation

Other outcomes

  1. Brain volume

    Will be measured by MRI - T1-weighted images and express in cm³

    Time frame: 1 day at baseline

  2. Rey Auditory Verbal Learning Test (RAVLT)

    Assesses verbal memory. Total score (range: 0-75); higher scores indicate better performance

    Time frame: 1 day at baseline

  3. Stroop Color and Word test (Stroop Test) (secondes)

    Measures processing speed and executive function; outcome is time to completion. Unit of Measure: Seconds; lower scores indicate better performance

    Time frame: 1 day at baseline

  4. Trail making test (secondes)

    Assesses cognitive flexibility, visual attention, and processing speed. Unit of Measure: Seconds; lower scores indicate better performance

    Time frame: 1 day at baseline

  5. Montreal Cognitive Assessment (MoCA) score

    Global cognitive screening tool. Unit of Measure: Score (range: 0-30); higher scores indicate better cognition.

    Time frame: 1 day at baseline

  6. Boston naming tests (total answer)

    Measures language and word retrieval ability.Total correct responses (range: 0-60); higher scores are better

    Time frame: 1 day at baseline

  7. Symbol coding (score)

    Assesses processing speed.Score (higher = better)

    Time frame: 1 day at baseline

  8. Logical Memory Subtest of the Wechsler Memory Scale-IV

    Assesses elayed story recall. Score (0-25); higher scores indicate better memory

    Time frame: 1 day at baseline

  9. Fasting plasma glucose (mM)

    Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups

    Time frame: 1 day at baseline

  10. Fasting plasma insulin (mM)

    Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups

    Time frame: 1 day at baseline

  11. Fasting plasma HbA1c (%)

    Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups

    Time frame: 1 day at baseline

  12. Fasting plasma total ketone (uM)

    Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups. Total ketone = acetoacetate + beta-hydroxybutyrate

    Time frame: 1 day at baseline

  13. Estrogene levels (pmol/L)

    Blood samples will be used to assess sex hormone and will be compared across 3 group

    Time frame: 1 day at baseline

  14. follicule stimulating hormone levels (mIU/mL)

    Blood samples will be used to assess sex hormone and will be compared across 3 group

    Time frame: 1 day at baseline

  15. Progesterone (nmol/L)

    Blood samples will be used to assess sex hormone and will be compared across 3 group

    Time frame: 1 day at baseline

  16. hormone lutéinisante (mUI/mL)

    Blood samples will be used to assess sex hormone and will be compared across 3 group

    Time frame: 1 day at baseline

  17. Menopause-Specific Quality of Life Questionnaire

    Self-reported questionnaires. Self-reported symptom burden. Unit of Measure: Score (range: 0-44); higher = more severe symptoms

    Time frame: 1 day at baseline

  18. Menopause Rating Scale

    Self-reported symptom burden. Unit of Measure: Score (range: 0-44); higher = more severe symptoms

    Time frame: 1 day at baseline

  19. Pittsburgh Sleep Quality Index

    Self-reported questionnaire. Assesses sleep quality over the past month. Unit of Measure: Score (range: 0-21); higher = poorer sleep

    Time frame: 1 day at baseline

  20. Patient Health Questionnaire (PHQ-9)

    Depressive symptoms. Score (range: 0-27); higher = more severe depression

    Time frame: 1 day at baseline

  21. Subjective memory complain

    Self-reported memory or concentration issues. Unit of Measure: Score (range 62-372) ; higher scores indicate more complaints

    Time frame: 1 day at baseline

  22. International Physical Activity Questionnaire

    Physical activity over the past week. (MET-minutes/week)

    Time frame: 1 day at baseline

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Andy C, Nerattini M, Jett S, Carlton C, Zarate C, Boneu C, Fauci F, Ajila T, Battista M, Pahlajani S, Christos P, Fink ME, Williams S, Brinton RD, Mosconi L. Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Front Endocrinol (Lausanne). 2024 Mar 4;15:1350318. doi: 10.3389/fendo.2024.1350318. eCollection 2024. PubMed 38501109 ↗
  • Castellano CA, Baillargeon JP, Nugent S, Tremblay S, Fortier M, Imbeault H, Duval J, Cunnane SC. Regional Brain Glucose Hypometabolism in Young Women with Polycystic Ovary Syndrome: Possible Link to Mild Insulin Resistance. PLoS One. 2015 Dec 9;10(12):e0144116. doi: 10.1371/journal.pone.0144116. eCollection 2015. PubMed 26650926 ↗
  • Mosconi L, Nerattini M, Matthews DC, Jett S, Andy C, Williams S, Yepez CB, Zarate C, Carlton C, Fauci F, Ajila T, Pahlajani S, Andrews R, Pupi A, Ballon D, Kelly J, Osborne JR, Nehmeh S, Fink M, Berti V, Dyke JP, Brinton RD. In vivo brain estrogen receptor density by neuroendocrine aging and relationships with cognition and symptomatology. Sci Rep. 2024 Jun 20;14(1):12680. doi: 10.1038/s41598-024-62820-7. PubMed 38902275 ↗
  • Paquette M, Phoenix S, Lavallee E, Rousseau JA, Guerin B, Turcotte EE, Lecomte R. Cross-Species Physiological Assessment of Brain Estrogen Receptor Expression Using 18F-FES and 18F-4FMFES PET Imaging. Mol Imaging Biol. 2020 Oct;22(5):1403-1413. doi: 10.1007/s11307-020-01520-w. Epub 2020 Jul 22. PubMed 32699974 ↗
  • Arjmand S, Bender D, Jakobsen S, Wegener G, Landau AM. Peering into the Brain's Estrogen Receptors: PET Tracers for Visualization of Nuclear and Extranuclear Estrogen Receptors in Brain Disorders. Biomolecules. 2023 Sep 18;13(9):1405. doi: 10.3390/biom13091405. PubMed 37759805 ↗
  • Fortier M, Castellano CA, St-Pierre V, Myette-Cote E, Langlois F, Roy M, Morin MC, Bocti C, Fulop T, Godin JP, Delannoy C, Cuenoud B, Cunnane SC. A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT. Alzheimers Dement. 2021 Mar;17(3):543-552. doi: 10.1002/alz.12206. Epub 2020 Oct 26. PubMed 33103819 ↗
  • Fortier M, Castellano CA, Croteau E, Langlois F, Bocti C, St-Pierre V, Vandenberghe C, Bernier M, Roy M, Descoteaux M, Whittingstall K, Lepage M, Turcotte EE, Fulop T, Cunnane SC. A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimers Dement. 2019 May;15(5):625-634. doi: 10.1016/j.jalz.2018.12.017. Epub 2019 Apr 23. PubMed 31027873 ↗
  • Croteau E, Castellano CA, Richard MA, Fortier M, Nugent S, Lepage M, Duchesne S, Whittingstall K, Turcotte EE, Bocti C, Fulop T, Cunnane SC. Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer's Disease. J Alzheimers Dis. 2018;64(2):551-561. doi: 10.3233/JAD-180202. PubMed 29914035 ↗
  • Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mithieux G, Moreira PI, Murphy MP, Nave KA, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Swerdlow RH, Millan MJ. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020 Sep;19(9):609-633. doi: 10.1038/s41573-020-0072-x. Epub 2020 Jul 24. PubMed 32709961 ↗
  • Mosconi L, Brinton RD. How would we combat menopause as an Alzheimer's risk factor? Expert Rev Neurother. 2018 Sep;18(9):689-691. doi: 10.1080/14737175.2018.1510320. Epub 2018 Aug 13. No abstract available. PubMed 30091648 ↗
  • Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Osorio RS, Connaughty C, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Swerdlow RH, Brinton RD. Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. PLoS One. 2017 Oct 10;12(10):e0185926. doi: 10.1371/journal.pone.0185926. eCollection 2017. PubMed 29016679 ↗
  • Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Varsavsky I, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Brinton RD. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. Neurology. 2017 Sep 26;89(13):1382-1390. doi: 10.1212/WNL.0000000000004425. Epub 2017 Aug 30. PubMed 28855400 ↗
  • Snyder HM, Asthana S, Bain L, Brinton R, Craft S, Dubal DB, Espeland MA, Gatz M, Mielke MM, Raber J, Rapp PR, Yaffe K, Carrillo MC. Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative. Alzheimers Dement. 2016 Nov;12(11):1186-1196. doi: 10.1016/j.jalz.2016.08.004. Epub 2016 Sep 27. PubMed 27692800 ↗
  • Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame N, Salamone L, Stellato R. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000 Sep 1;152(5):463-73. doi: 10.1093/aje/152.5.463. PubMed 10981461 ↗
  • Delanerolle G, Phiri P, Elneil S, Talaulikar V, Eleje GU, Kareem R, Shetty A, Saraswath L, Kurmi O, Benetti-Pinto CL, Muhammad I, Rathnayake N, Toh TH, Aggarwal IM, Shi JQ, Taylor J, Riach K, Potocnik K, Litchfield I, Kemp HF, Briggs P; MARIE collaborative. Menopause: a global health and wellbeing issue that needs urgent attention. Lancet Glob Health. 2025 Feb;13(2):e196-e198. doi: 10.1016/S2214-109X(24)00528-X. Epub 2024 Dec 18. No abstract available. PubMed 39708829 ↗
  • Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012 Apr;97(4):1159-68. doi: 10.1210/jc.2011-3362. Epub 2012 Feb 16. PubMed 22344196 ↗
  • Mosconi L, Rahman A, Diaz I, Wu X, Scheyer O, Hristov HW, Vallabhajosula S, Isaacson RS, de Leon MJ, Brinton RD. Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. PLoS One. 2018 Dec 12;13(12):e0207885. doi: 10.1371/journal.pone.0207885. eCollection 2018. PubMed 30540774 ↗

Individual participant data

Plan to share: Undecided — There is no current plan to share individual participant data (IPD) with external researchers. While data reuse within the study team is permitted, external data sharing is subject to sponsor agreement and may be considered on a case-by-case basis in the future.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Mar 2026 → Apr 2027 and completion Jul 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
Jun 15, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Apr 1, 2027was Mar 2026
CompletionEst.
Sep 1, 2027was Jul 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
1 site added. Centre de recherche sur le Vieillissement is now Not yet recruiting
Show site
  • Research Center on Aging · Sherbrooke, Canada
Oct 26, 2026
Primary completion
Mar 1, 2026→Apr 1, 2027
Oct 26, 2026
Study completion
Jul 1, 2026→Sep 1, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    1 site added. Centre de recherche sur le Vieillissement is now Not yet recruiting
    Show site
    • Research Center on Aging · Sherbrooke, Canada
    Primary completion Mar 1, 2026→Apr 1, 2027
    Study completion Jul 1, 2026→Sep 1, 2027
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07021664
Collaborators
Nestlé Health Science
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Jul 1, 2025
Primary completion
Apr 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Melanie Fortier, M.Sc.
Contact
recherche.cerveau@usherbrooke.ca
1-819-821-5206
Stephen Cunnane, Ph.D
principal investigator · Université de Sherbrooke

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion